Seres Therapeutics, Inc.
Seres Therapeutics is a clinical-stage company that discovers and develops oral live biotherapeutic products made from bacterial consortia to address diseases associated with the gut microbiome, including infections and inflammatory and immune diseases. Its pipeline includes SER-155, being evaluated for immune checkpoint-related enterocolitis and developed to prevent infections in medically vulnerable patients; SER-603, in development for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and SER-147, designed to prevent infections in patients with metabolic disease, including chronic liver disease. Seres is also developing an oral liquid formulation based on SER-155 strains. It previously developed VOWST, an FDA-approved oral microbiome therapeutic, which it sold to Nestlé Health Science in September 2024. Seres uses its microbiome discovery and development platform to identify bacterial strains, design product candidates, and conduct preclinical and clinical development. Its capabilities include manufacturing live biotherapeutics under current good manufacturing practices. The company is headquartered in Cambridge, Massachusetts.
No SEC Form 4 filings for $MCRB in the last 30 days.
See all $MCRB insider activity →Seres Therapeutics Inc (MCRB) reported Q3 EPS of -$1.63, beating estimates by $0.01, but revenue of $590K missed expectations of $12.5M. The stock is down 59.75% over 3 months and 84.57% over 12 months, with a 'weak performance' financial health score according to InvestingPro.
Seres Therapeutics (MCRB) reported Q3 GAAP EPS of -$1.63, missing estimates by $0.63. Revenue was $0.59M, down $5.76M from expectations, despite a 68.6% year-over-year increase. Shares fell 11% post-market.
Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI)
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MCRB (Seres Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent MCRB coverage spans earnings, corporate actions and technology.
Revenue miss likely triggers further downside despite EPS beat.
Earnings miss drives negative sentiment and short‑term pressure on the stock.
Positive early‑stage trial data and a clear development plan for SER‑155 may lift the stock.
Leadership change may cause short‑term stock pressure.
The CFO departure introduces leadership uncertainty which may weigh on the stock.
AlphAI scores every news story that mentions MCRB with an AI model for sentiment and relevance, and aggregates insider trades from Seres Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Seres Therapeutics Inc (MCRB) reported Q3 EPS of -$1.63, beating estimates by $0.01, but revenue of $590K missed expectations of $12.5M. The stock is down 59.75% over 3 months and 84.57% over 12 months, with a 'weak performance' financial health score according to InvestingPro.
2 min readSeres Therapeutics (MCRB) reported Q3 GAAP EPS of -$1.63, missing estimates by $0.63. Revenue was $0.59M, down $5.76M from expectations, despite a 68.6% year-over-year increase. Shares fell 11% post-market.
1 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI)
2 min readSeres Therapeutics CFO Marella Thorell will resign on November 15, 2026, and provide advisory services during the transition. The company has not disclosed a reason or replacement. (Source: SEC filing)
1 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (th
1 min readSeres Therapeutics (MCRB) will present preclinical data on SER-428, an investigational oral liquid live biotherapeutic, at IDWeek 2026. SER-428 aims to reduce bloodstream infections in high-risk patients post-sepsis. Preclinical results show significant reduction in pathogens. The company plans a Phase 1b trial, pending funding. Development is supported by CARB-X.
2 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for im
6 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Lease Amendment and Termination Agreement On July 31, 2026 (the “Execution Date”), Seres Therapeutics, Inc. (the “Company”) entered into the Third Amendment to Lease and Termination Agreement (the “Termination Agreement”) wit
4 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d100733dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 S ERES T HERAPEUTICS , I NC . 2025 I NCENTIVE A WARD P LAN ( AS AMENDED AND RESTATED EFFECTIVE July 8, 2026) I. P URPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who mak
2 min readSeres Therapeutics (Nasdaq: MCRB) said it will host a webcast on July 8, 2026 (8:30 a.m. ET) to discuss top-line results from an investigator-sponsored trial at Memorial Sloan Kettering of SER-155 in immune checkpoint inhibitor-related enterocolitis. The open-label study enrolled 15 patients with Grade 2–3 irEC; the primary endpoint is an immunosuppressive-free clinical response on Day 15.
3 min read
